<?xml version="1.0" encoding="UTF-8"?>
<clinical_study>
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 23, 2024</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT01402154</url>
  </required_header>
  <id_info>
    <org_study_id>AOI/2010/SD-01</org_study_id>
    <secondary_id>2011-A00328-33</secondary_id>
    <nct_id>NCT01402154</nct_id>
  </id_info>
  <brief_title>EPISPOT Detection of Circulating Prostate Cells Among Adenocarcinoma Patients</brief_title>
  <official_title>The Pre-treatment Detection of Circulating, Functional, Prostate Cells Among Adenocarcinoma Patients: an Evaluation of the EPISPOT Technique</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>The primary objective of this study is to evaluate the predictive value (in terms of&#xd;
remission) of a new technique for detecting circulating, functional, prostate cells among&#xd;
patients with localized adenocarcinoma of the prostate, and prior to any treatment.</textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">January 3, 2012</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">December 8, 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The difference between AUCs for the EPISPOT and Cellsearch Techniques</measure>
    <time_frame>1 day</time_frame>
    <description>The difference between the AUCs (area under the curve) for the EPISPOT and Cellsearch&#xd;
techniques for detecting functional, circulating prostate cells</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">361</enrollment>
  <condition>Adenocarcinoma of the Prostate</condition>
  <arm_group>
    <arm_group_label>All study patients</arm_group_label>
    <description>All patients included according to stated inclusion and exclusion criteria.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EPISPOT detection of the number of circulating cells</intervention_name>
    <description>EPISPOT detection of the number of circulating, functional, prostate cells per unit blood</description>
    <arm_group_label>All study patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CellSearch detection of the number of circulating, functional, prostate cells</intervention_name>
    <description>CellSearch detection of the number of circulating, functional, prostate cells per unit&#xd;
blood</description>
    <arm_group_label>All study patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>Following the completion of the biological analyses required for this study, leftover&#xd;
tubes may be placed in the Nîmes University Hospital biological collection for future&#xd;
ancillary studies, if patients are agreed with this. The samples concerned include EDTA&#xd;
and CellSave tubes for each patient.</textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>Patients with histologically proven, localized, adenocarcinoma of the prostate who accept&#xd;
a curative treatment.</textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>Inclusion Criteria:&#xd;
&#xd;
  -  The patient must have given his/her informed and signed consent&#xd;
&#xd;
  -  The patient must be insured or beneficiary of a health insurance plan&#xd;
&#xd;
  -  Histologically proven presence of prostate adenocarcinoma&#xd;
&#xd;
  -  Localized disease on digital rectal examination&#xd;
&#xd;
  -  Cancer without extensions&#xd;
&#xd;
  -  Acceptance of a curative treatment by the patient&#xd;
&#xd;
Exclusion Criteria:&#xd;
&#xd;
  -  The patient is participating in another study&#xd;
&#xd;
  -  The patient is in an exclusion period determined by a previous study&#xd;
&#xd;
  -  The patient is under judicial protection, under tutorship or curatorship&#xd;
&#xd;
  -  The patient refuses to sign the consent&#xd;
&#xd;
  -  It is impossible to correctly inform the patient&#xd;
&#xd;
  -  The patient is taking a hormone-modifying treatment&#xd;
&#xd;
  -  Patient taking adrogenic supplements</textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stéphane Droupy, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Nîmes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Nîmes - Hôpital Universitaire Carémeau</name>
      <address>
        <city>Nîmes Cedex 09</city>
        <state>Gard</state>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier - Hôpital Lapeyronie - Plateforme LCCRH</name>
      <address>
        <city>Montpellier Cedex 05</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier - Hôpital Lapeyronie</name>
      <address>
        <city>Montpellier Cedex 05</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Beau Soleil</name>
      <address>
        <city>Montpellier</city>
        <zip>34070</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional de Lutte Contre le Cancer - Val d'Aurelle - Paul Lamarque</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 25, 2011</study_first_submitted>
  <study_first_submitted_qc>July 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2011</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
</clinical_study>
